164 related articles for article (PubMed ID: 15846528)
1. Reassessment of the benefit/risk-ratio of selective COX-2-inhibitors.
Klotz U
Swiss Med Wkly; 2005 Mar; 135(11-12):166-8. PubMed ID: 15846528
[No Abstract] [Full Text] [Related]
2. COX-2 inhibitors still eyed for cancer prevention.
Thompson CA
Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492
[No Abstract] [Full Text] [Related]
3. A tale of two coxibs.
Hegmann T
JAAPA; 2005 Mar; 18(3):14, 17. PubMed ID: 15789666
[No Abstract] [Full Text] [Related]
4. COX-2 inhibitors: cancer prevention or cardiovascular risk?
Senior K
Lancet Oncol; 2005 Feb; 6(2):68. PubMed ID: 15704289
[No Abstract] [Full Text] [Related]
5. Decisions loom on selective COX-2 inhibitors.
Miller JL
Am J Health Syst Pharm; 1999 Jan; 56(2):106-7. PubMed ID: 10030522
[No Abstract] [Full Text] [Related]
6. Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib.
Brinker A; Nourjah P
Am J Health Syst Pharm; 2005 Apr; 62(7):739-43. PubMed ID: 15790802
[No Abstract] [Full Text] [Related]
7. Tailoring arthritis therapy in the wake of the NSAID crisis.
Olsen NJ
N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
[No Abstract] [Full Text] [Related]
8. Selective COX-2 inhibitors.
Pasero C; McCaffery M
Am J Nurs; 2001 Apr; 101(4):55-6. PubMed ID: 11301685
[No Abstract] [Full Text] [Related]
9. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
Rioda WT; Nervetti A
Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
[TBL] [Abstract][Full Text] [Related]
10. The new NSAIDs: cox-2 inhibitors.
Capriotti T
Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
[No Abstract] [Full Text] [Related]
11. The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats.
El-Medany A; Mahgoub A; Mustafa A; Arafa M; Morsi M
Eur J Pharmacol; 2005 Jan; 507(1-3):291-9. PubMed ID: 15659320
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
[TBL] [Abstract][Full Text] [Related]
13. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
14. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
Nelson MR
Med J Aust; 2004 Feb; 180(3):140. PubMed ID: 14748681
[No Abstract] [Full Text] [Related]
15. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
Patrignani P
Acta Otorhinolaryngol Ital; 2003 Aug; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
[No Abstract] [Full Text] [Related]
16. Early trials probe COX-2 inhibitors' cancer-fighting potential.
Ziegler J
J Natl Cancer Inst; 1999 Jul; 91(14):1186-7. PubMed ID: 10413412
[No Abstract] [Full Text] [Related]
17. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
Bardou M; Barkun AN; Ghosn J; Hudson M; Rahme E
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):880-7. PubMed ID: 15476151
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory medications: selective COX-2 inhibitors.
Lane JM
J Am Acad Orthop Surg; 2002; 10(2):75-8. PubMed ID: 11929201
[No Abstract] [Full Text] [Related]
19. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
Henderson P
JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939848
[No Abstract] [Full Text] [Related]
20. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
Bierma-Zeinstra SM; Bohnen AM; Berger MY; Thomas S
JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
